Elisabeth M Dykens1,2, Elizabeth Roof1, Hailee Hunt-Hawkins1. 1. Kennedy Center for Research on Human Development, Vanderbilt University, Nashville, TN, USA. 2. Departments of Psychology and Human Development, Psychiatry and Pediatrics, Vanderbilt University, Nashville, TN, USA.
Abstract
BACKGROUND: People with Prader-Willi syndrome (PWS) typically have mild to moderate intellectual deficits, compulsivity, hyperphagia, obesity, and growth hormone deficiencies. Growth hormone treatment (GHT) in PWS has well-established salutatory effects on linear growth and body composition, yet cognitive benefits of GHT, seen in other patient groups, have not been well studied in PWS. METHODS: Study 1 included 96 children and youth with PWS aged 4-21 years who naturalistically varied in their exposures to GHT. Controlling for socioeconomic status, analyses compared cognitive and adaptive behavior test scores across age-matched treatment naïve versus growth hormone treated children. Study II assessed if age of treatment initiation or treatment duration was associated with subsequent cognition or adaptive behavior in 127, 4- to 21-year olds with PWS. Study III longitudinally examined cognitive and adaptive behavior in 168 participants who were either consistently on versus off GHT for up to 4-5 years. RESULTS: Compared to the treatment naïve group, children receiving GHT had significantly higher Verbal and Composite IQs, and adaptive communication and daily living skills. Children who began treatment before 12 months of age had higher Nonverbal and Composite IQs than children who began treatment between 1 and 5 years of age. Longitudinally, the groups differed in their intercepts, but not slopes, with each group showing stable IQ and adaptive behavior scores over time. CONCLUSIONS: Cognitive and adaptive advantages should be considered an ancillary benefit and additional justification for GHT in people with PWS. Future efforts need to target apparent socioeconomic inequities in accessing GHT in the PWS population.
BACKGROUND:People with Prader-Willi syndrome (PWS) typically have mild to moderate intellectual deficits, compulsivity, hyperphagia, obesity, and growth hormone deficiencies. Growth hormone treatment (GHT) in PWS has well-established salutatory effects on linear growth and body composition, yet cognitive benefits of GHT, seen in other patient groups, have not been well studied in PWS. METHODS: Study 1 included 96 children and youth with PWS aged 4-21 years who naturalistically varied in their exposures to GHT. Controlling for socioeconomic status, analyses compared cognitive and adaptive behavior test scores across age-matched treatment naïve versus growth hormone treated children. Study II assessed if age of treatment initiation or treatment duration was associated with subsequent cognition or adaptive behavior in 127, 4- to 21-year olds with PWS. Study III longitudinally examined cognitive and adaptive behavior in 168 participants who were either consistently on versus off GHT for up to 4-5 years. RESULTS: Compared to the treatment naïve group, children receiving GHT had significantly higher Verbal and Composite IQs, and adaptive communication and daily living skills. Children who began treatment before 12 months of age had higher Nonverbal and Composite IQs than children who began treatment between 1 and 5 years of age. Longitudinally, the groups differed in their intercepts, but not slopes, with each group showing stable IQ and adaptive behavior scores over time. CONCLUSIONS: Cognitive and adaptive advantages should be considered an ancillary benefit and additional justification for GHT in people with PWS. Future efforts need to target apparent socioeconomic inequities in accessing GHT in the PWS population.
Authors: Nienke E Bakker; Elbrich P C Siemensma; Marjon van Rijn; Dederieke A M Festen; Anita C S Hokken-Koelega Journal: Horm Res Paediatr Date: 2015-08-13 Impact factor: 2.852
Authors: Elbrich P C Siemensma; Roderick F A Tummers-de Lind van Wijngaarden; Dederieke A M Festen; Zyrhea C E Troeman; A A E M Janielle van Alfen-van der Velden; Barto J Otten; Joost Rotteveel; Roelof J H Odink; G C B Karen Bindels-de Heus; Mariette van Leeuwen; Danny A J P Haring; Wilma Oostdijk; Gianni Bocca; E C A Mieke Houdijk; A S Paul van Trotsenburg; J J Gera Hoorweg-Nijman; Hester van Wieringen; René C F M Vreuls; Petr E Jira; Eelco J Schroor; Evelyn van Pinxteren-Nagler; Jan Willem Pilon; L Bert Lunshof; Anita C S Hokken-Koelega Journal: J Clin Endocrinol Metab Date: 2012-04-16 Impact factor: 5.958
Authors: A Takeda; K Cooper; A Bird; L Baxter; G K Frampton; E Gospodarevskaya; K Welch; J Bryant Journal: Health Technol Assess Date: 2010-09 Impact factor: 4.014
Authors: Harriette R Mogul; Phillip D K Lee; Barbara Y Whitman; William B Zipf; Michael Frey; Susan Myers; Mindy Cahan; Belinda Pinyerd; A Louis Southren Journal: J Clin Endocrinol Metab Date: 2008-01-22 Impact factor: 5.958
Authors: Merlin G Butler; Naomi A Matthews; Nidhi Patel; Abhilasha Surampalli; June-Anne Gold; Manaswitha Khare; Travis Thompson; Suzanne B Cassidy; Virginia E Kimonis Journal: Am J Med Genet A Date: 2019-07-16 Impact factor: 2.802
Authors: Elisabeth M Dykens; Elizabeth Roof; Hailee Hunt-Hawkins; Nathan Dankner; Evon Batey Lee; Carolyn M Shivers; Christopher Daniell; Soo-Jeong Kim Journal: J Neurodev Disord Date: 2017-06-05 Impact factor: 4.025
Authors: Jessica Duis; Pieter J van Wattum; Ann Scheimann; Parisa Salehi; Elly Brokamp; Laura Fairbrother; Anna Childers; Althea Robinson Shelton; Nathan C Bingham; Ashley H Shoemaker; Jennifer L Miller Journal: Mol Genet Genomic Med Date: 2019-01-29 Impact factor: 2.183
Authors: Elisabeth M Dykens; Elizabeth Roof; Hailee Hunt-Hawkins; Christopher Daniell; Sarah Jurgensmeyer Journal: PLoS One Date: 2019-10-17 Impact factor: 3.240